Advertisement
CI vs CVS
Which Stock Would AI Choose? Cigna Group (CI) vs. CVS Health (CVS) Stock Comparison
Key Takeaways
- CI is a diversified health services and benefits provider with strong specialty pharmacy momentum, but its shares have lagged the sector over the past year.
- CVS has delivered a powerful turnaround, beating earnings expectations for five consecutive quarters and sharply raising full-year guidance.
- The two companies diverge in momentum: CVS has rallied while CI has drifted lower, even as CI trades at a discount to industry valuations.
- Both face regulatory and reimbursement scrutiny around pharmacy benefit managers (PBMs), a shared risk that shapes sentiment across the sector.
- Business models differ materially — CI leans into employer health plans and specialty services, while CVS spans insurance, retail pharmacy, and PBMs.
Introduction
Investors evaluating the managed care and pharmacy services space often weigh CI against CVS because the two companies sit at the center of overlapping healthcare economics — insurance, pharmacy benefits, and specialty drug distribution. Yet their recent trajectories have diverged sharply. This stock comparison examines relative performance, growth drivers, and market positioning to help traders and long-term investors understand where each name stands today. Whether you are tracking momentum or seeking value, the contrast between these two healthcare giants offers a useful lens on a sector navigating elevated medical costs, PBM reform, and evolving consumer expectations.
CI Overview and Recent Performance
The Cigna Group (CI) operates through two primary divisions: Cigna Healthcare, which provides employer-sponsored and international medical plans, and Evernorth Health Services, which spans pharmacy benefits, specialty pharmacy, and care services. In recent weeks, the company reported strong quarterly results, raising its full-year adjusted earnings outlook to at least $30.35 per share, supported by growth across both divisions. Its Specialty and Care Services unit has been a standout, with pretax adjusted earnings expanding roughly 20% year over year, aided by rising biosimilar adoption and specialty generics.
Despite solid fundamentals, CI shares have been a relative laggard. The stock has declined over the past year and trades at a forward price-to-earnings (P/E) ratio well below the industry average, reflecting lingering concerns around PBM regulation, client transitions, and the strategic reshaping of its portfolio — including its earlier divestiture of Medicare assets and a planned exit from the individual exchange market. A low valuation, a dividend yield near 2.2%, and aggressive share buybacks continue to attract value-oriented investors, even as sentiment remains cautious.
CVS Overview and Recent Performance
CVS Health (CVS) is a vertically integrated healthcare company operating three segments: Health Care Benefits (through Aetna), Health Services (including the Caremark PBM), and Pharmacy & Consumer Wellness, anchored by the nation's largest retail pharmacy chain. After a difficult stretch marked by elevated medical costs and leadership changes, the company has executed a multi-year turnaround involving roughly $2 billion in cost cuts, store closures, and a recovery in its insurance margins.
In recent market activity, CVS has been a notable outperformer. The company has beaten Wall Street expectations for five consecutive quarters and raised its full-year adjusted earnings guidance materially, to a range of $7.90 to $8.10 per share, while lifting revenue and cash-flow outlooks. A sharp improvement in Aetna's medical benefit ratio (a measure of claims paid relative to premiums collected) has been central to the rally, which has driven shares up more than 30% over the past year. Still, cautionary signals remain — including expected Caremark membership declines and a 340B-related reimbursement headwind that management sees persisting into 2027.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots actively navigating current market conditions. Tickeron hosts hundreds of AI Trading Bots covering thousands of tickers, but only those most suited to today's environment earn a place in this featured section. Each bot employs a distinct trading style, strategy, and timeframe, with its own performance history, statistical profile, and set of tickers it trades. This diversity lets users identify approaches aligned with their risk tolerance and objectives, whether they favor short-term momentum or longer-horizon positioning. Exploring the Trending AI Robots can help you see which strategies are currently resonating in the market.
Head-to-Head Comparison
The most striking contrast between CI and CVS is momentum versus valuation. CVS has rewarded investors with a multi-quarter earnings recovery and strong share-price gains, while CI has delivered consistent earnings growth yet seen its stock stagnate — creating a value-versus-momentum trade-off. CI's forward P/E sits well below the industry average, whereas CVS's rally has compressed its discount but left it with a price-to-sales ratio still below peer norms.
Their business models also diverge. CI is increasingly focused on employer health plans and specialty pharmacy services after exiting Medicare, positioning it toward commercial stability and high-growth specialty segments. CVS remains more diversified and more exposed to government programs, including Medicare Advantage, which carries both higher regulatory risk and a more direct turnaround narrative. Both companies face overlapping headwinds from PBM reform and drug-pricing scrutiny, but CVS's vertical integration — pairing a PBM with retail pharmacies — attracts distinct state-level legal and competitive attention. Growth drivers differ as well: CI leans on specialty and biosimilar expansion, while CVS emphasizes insurance margin recovery, retail prescription growth, and AI-enabled consumer engagement.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor CVS in the current environment. The stock's trend consistency, consecutive earnings beats, and upward guidance revisions suggest stronger near-term momentum and improving relative positioning. CI's discounted valuation and resilient specialty franchise give it appeal, but its softer price trend and ongoing portfolio transition introduce more near-term uncertainty. The AI's preference is probabilistic rather than definitive: CVS appears to offer the more favorable blend of trend strength, catalysts, and improving fundamentals, while CI remains a compelling watch for investors prioritizing valuation over momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CI is a Hold and CVS is a Buy.
CI | CVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 51 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 61 | 83 | |
SMR RATING 1..100 | 54 | 81 | |
PRICE GROWTH RATING 1..100 | 55 | 56 | |
P/E GROWTH RATING 1..100 | 74 | 31 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CVS's Valuation (2) in the Drugstore Chains industry is in the same range as CI (5) in the Managed Health Care industry. This means that CVS’s stock grew similarly to CI’s over the last 12 months.
CI's Profit vs Risk Rating (61) in the Managed Health Care industry is in the same range as CVS (83) in the Drugstore Chains industry. This means that CI’s stock grew similarly to CVS’s over the last 12 months.
CI's SMR Rating (54) in the Managed Health Care industry is in the same range as CVS (81) in the Drugstore Chains industry. This means that CI’s stock grew similarly to CVS’s over the last 12 months.
CI's Price Growth Rating (55) in the Managed Health Care industry is in the same range as CVS (56) in the Drugstore Chains industry. This means that CI’s stock grew similarly to CVS’s over the last 12 months.
CVS's P/E Growth Rating (31) in the Drugstore Chains industry is somewhat better than the same rating for CI (74) in the Managed Health Care industry. This means that CVS’s stock grew somewhat faster than CI’s over the last 12 months.
| CI | CVS | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 67% |
| Stochastic ODDS (%) | 2 days ago 61% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 50% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 60% | 2 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 61% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 51% | 2 days ago 57% |
| Advances ODDS (%) | 23 days ago 63% | N/A |
| Declines ODDS (%) | 2 days ago 55% | 2 days ago 60% |
| BollingerBands ODDS (%) | 2 days ago 53% | 2 days ago 75% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CI’s FA Score shows that 1 FA rating(s) are green while CVS’s FA Score has 2 green FA rating(s).
- CI’s FA Score: 1 green, 4 red.
- CVS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CI’s TA Score shows that 3 TA indicator(s) are bullish while CVS’s TA Score has 3 bullish TA indicator(s).
- CI’s TA Score: 3 bullish, 6 bearish.
- CVS’s TA Score: 3 bullish, 4 bearish.
Price Growth
CI (@Managed Health Care) experienced а +0.93% price change this week, while CVS (@Managed Health Care) price change was +0.18% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was -0.93%. For the same industry, the average monthly price growth was -7.57%, and the average quarterly price growth was +57.20%.
Reported Earning Dates
CI is expected to report earnings on Oct 29, 2026.
CVS is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Managed Health Care (-0.93% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
Advertisement
CI and
Correlation & Price change
A.I.dvisor indicates that over the last year, CI has been loosely correlated with CVS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CI jumps, then CVS could also see price increases.
CVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CVS has been closely correlated with UNH. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if CVS jumps, then UNH could also see price increases.